BioSpace News Archive

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has received clearance from the U.S. Food & Drug Administration (FDA) to market its reverse shoulder system

Iterative Scopes, a leading Artificial Intelligence in Gastroenterology provider, today announced the expansion of its world class Scientific Advisory Board with experts in the field of Artificial Intelligence (AI) and IBD.

2020 saw the announcement of a strategic partnership between Nestlé Health Science and VALBIOTIS for the development and marketing of TOTUM-63 (Press release of February 5, 2020)

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute (“UCRI”) to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.

Tree of Knowledge International Inc. (CSE:TOKI) (“TOKI” or the “Company”) is pleased to provide the following update as to the business and operations of TOKI. As previously announced, the Board has determined May 19, 2021 as the date on which it plans to hold the annual general meeting of the Company.

Psychemedics Corporation announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately.

Piezo Motion Corp, a U.S. leader of precision motor technology, today announced the launch of its piezoelectric micro-dosing pump (https://pages.piezomotion.com/micro-dosing-pump)

Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will present safety, efficacy, and patient-reported outcomes from its Phase 2 open-label long-term safety study investigating roflumilast 0.3% cream in adult patients